METASTATIC PROSTATE ADENOCARCINOMA
Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug combo aims to halt advanced prostate cancer in select patients
Disease control OngoingThis study is testing a combination of two drugs, niraparib/abiraterone and prednisone, in men with advanced prostate cancer that has spread and has stopped responding to standard hormone-blocking treatments. The treatment is specifically for patients whose cancer has a particula…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Two-Drug combo aims to rally immune system against tough prostate cancer
Disease control TerminatedThis study is testing whether combining two immunotherapy drugs, vidutolimod and nivolumab, can help the body's immune system find and kill prostate cancer cells that have spread. It is for men whose cancer has stopped responding to standard hormone therapy and chemotherapy. The …
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Shorter radiation course tested for prostate cancer that has returned
Disease control OngoingThis study is testing if a shorter, more intense course of radiation is safe and effective for men whose prostate cancer has returned or spread to a few lymph nodes. It compares two radiation methods—proton therapy and standard IMRT—to see which one causes fewer serious side effe…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Two-Pronged attack on advanced prostate cancer
Disease control OngoingThis study is testing a combination of two drugs, olaparib and radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can slow the cance…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug duo aims to outsmart advanced prostate cancer
Disease control OngoingThis study is testing if adding a drug called rucaparib to standard treatment (enzalutamide) works better for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the combination helps patients live longer or keeps their cancer fro…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Precision strike: new combo therapy aims to control spreading prostate cancer
Disease control OngoingThis study is testing a two-part treatment for prostate cancer that has returned and spread to a few other areas of the body. Patients receive hormone-blocking drugs for six months, combined with highly targeted radiation to the specific tumors. The goal is to see if this combine…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC